Loading
A phase 2 trial of Adebrelimab, Capecitabine, Cisplatin, Oxaliplatin and SHR-8068 in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer is a phase 2 interventional study registered as NCT06247956 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 153 participants enrolled, started 2024-03-11 and due to reach its primary completion in 2025-12-30. Interventions recorded: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection and Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection.
Shares Adebrelimab, Oxaliplatin, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.